Novavax, Inc. (NASDAQ:NVAX) has earned an average rating of “Hold” from the twelve brokerages that are currently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $28.14.
Several brokerages have commented on NVAX. Zacks Investment Research upgraded shares of Novavax from a “hold” rating to a “buy” rating and set a $8.00 price objective for the company in a research report on Thursday, May 16th. BidaskClub upgraded shares of Novavax from a “sell” rating to a “hold” rating in a research report on Thursday, March 21st. ValuEngine upgraded shares of Novavax from a “buy” rating to a “strong-buy” rating in a research report on Friday, May 10th. Cantor Fitzgerald set a $20.00 price objective on shares of Novavax and gave the company a “hold” rating in a research report on Tuesday, March 19th. Finally, LADENBURG THALM/SH SH restated a “buy” rating and set a $2.00 price objective on shares of Novavax in a research report on Tuesday.
In related news, Director Rachel K. King bought 86,000 shares of the firm’s stock in a transaction on Wednesday, March 27th. The shares were purchased at an average price of $0.53 per share, with a total value of $45,580.00. Following the completion of the purchase, the director now owns 42,000 shares in the company, valued at approximately $22,260. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 3.30% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of the business. IHT Wealth Management LLC grew its stake in shares of Novavax by 0.7% during the first quarter. IHT Wealth Management LLC now owns 233,855 shares of the biopharmaceutical company’s stock worth $129,000 after buying an additional 1,698 shares during the last quarter. Jane Street Group LLC grew its stake in shares of Novavax by 3.6% in the first quarter. Jane Street Group LLC now owns 320,289 shares of the biopharmaceutical company’s stock worth $176,000 after purchasing an additional 11,267 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. grew its stake in shares of Novavax by 14.4% in the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 166,350 shares of the biopharmaceutical company’s stock worth $91,000 after purchasing an additional 20,900 shares during the last quarter. Avenir Corp bought a new stake in shares of Novavax in the first quarter worth $120,000. Finally, Renaissance Technologies LLC grew its stake in shares of Novavax by 470.2% in the first quarter. Renaissance Technologies LLC now owns 2,417,664 shares of the biopharmaceutical company’s stock worth $1,332,000 after purchasing an additional 1,993,697 shares during the last quarter.
NVAX traded down $0.27 during trading on Tuesday, hitting $5.10. 759,065 shares of the stock traded hands, compared to its average volume of 839,503. Novavax has a twelve month low of $5.08 and a twelve month high of $51.60. The company has a market cap of $119.71 million, a P/E ratio of -0.51 and a beta of 2.32.
Novavax (NASDAQ:NVAX) last announced its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($2.20) EPS for the quarter, beating the consensus estimate of ($2.40) by $0.20. The firm had revenue of $3.98 million for the quarter, compared to analyst estimates of $4.80 million. During the same quarter in the prior year, the firm earned ($2.80) earnings per share. Equities analysts expect that Novavax will post -6.93 earnings per share for the current year.
Novavax, Inc, together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant that is in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase II clinical trial for treating seasonal influenza in older adults.
Featured Story: The mechanics of the bid-ask spread in trading
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.